Abstract
Summary: In our practice we often meet patients with advanced colorectal cancer who are in very good condition and have already exhausted at least two lines of palliative therapy based on oxaliplatin, irinotecan, fluoropyrimidines, antiangiogenic monoclonal antibodies and in RAS wild tumors and anti-EGFR monoclonal antibodies. In these cases, subsequent therapy with the composite cytostatic preparation tipiracil / trifluridine (Lonsurf) or the biological tyrosine kinase inhibitor regorafenib (Stivarga) may be considered.
Both preparations in their registration studies (RECOURSE, CORRECT) showed very similar efficacy but significantly different toxic profiles - while regorafenib caused significantly subjectively perceived toxicity to patients (diarrhea, hypertension, hand foot syndrome), tipiracil / trifluridine was subjectively perceived by patients. very low and neither haematotoxicity was usually accompanied by neither subjective problems nor the development of febrile neutropenia or bleeding thrombocytopenia. Maintaining a very good quality of life is a priority, especially for pre-treated patients.
The presented case report of a patient treated with the third palliative line is a typical example of quality anticancer treatment while maintaining a very good quality of life for our patient.